Premium
Pluripotent Stem Cell‐Based Platforms in Cardiac Disease Modeling and Drug Testing
Author(s) -
Shaheen N,
Shiti A,
Gepstein L
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.722
Subject(s) - induced pluripotent stem cell , drug discovery , genome editing , disease , precision medicine , drug , computational biology , drug development , human induced pluripotent stem cells , human disease , neuroscience , medicine , biology , crispr , bioinformatics , pharmacology , embryonic stem cell , pathology , genetics , gene
The ability to generate patient/disease‐specific human pluripotent stem cell (hPSC)‐derived cardiomyocytes (hPSC‐CMs) brings a unique value to the fields of cardiac disease modeling, drug testing, drug discovery, and precision medicine. Further integration of emerging innovative technologies such as developmental‐biology inspired differentiation into chamber‐specific cardiomyocyte subtypes, genome‐editing, tissue‐engineering, and novel functional phenotyping methodologies should facilitate even more advanced investigations. Here, we review cornerstone concepts and recent highlights of hPSC‐based cardiac disease modeling and drug testing.